(MENAFN- EIN Presswire)
Nonmelanoma Skin Cancer market Insights
Nonmelanoma Skin Cancer Market Forecast-2034 report offers an in-depth understanding of the forecasted epidemiology as well as the market trends in the 7MM.
LAS VEGAS, NV, UNITED STATES, December 17, 2024 /EINPresswire / --
DelveInsight's“Nonmelanoma Skin Cancer Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Nonmelanoma Skin Cancer, historical and forecasted epidemiology as well as the Nonmelanoma Skin Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Nonmelanoma Skin Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Nonmelanoma Skin Cancer Market Forecast
Some of the key facts of the Nonmelanoma Skin Cancer Market Report:
.The Nonmelanoma Skin Cancer market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
.In August 2024, SkinCure Oncology, a global leader in offering a comprehensive model for delivering Image-Guided Superficial Radiation Therapy (Image-Guided SRT), the leading nonsurgical treatment for common skin cancers, has announced the publication of a new study highlighting the importance of conducting full dermal visualization (FDV) through high-resolution dermal ultrasound (HRDUS) before each treatment fraction for nonmelanoma skin cancer (NMSC) using Image-Guided SRT.
.Basal cell carcinoma represents approximately 80% of all skin cancer cases and typically occurs in sun-exposed areas like the face and neck. Squamous cell carcinoma accounts for about 20% of the remaining skin cancer cases.
.Skin cancer is the most typical cancer, according to Cedars-Sinai (n.d.). Skin cancer accounts for between 40 and 50 percent of all cancer cases detected each year
.Goldenberg et al. (2016) conducted a retrospective cohort analysis using Truven Health MarketScan database insurance claims, enrolling patients 18 years of age or older with two or more BCC claims that were at least 30 days apart between October 2011 and September 2012. The age-adjusted prevalence rate for BCC patients was 342.64 per 100,000. The prevalence rates were higher in males than in females, higher in patients 65 years of age or older, and lowest in patients 18 to 24 years of age
.STP705, AIV001, RP1, and other new treatments for non-melanoma skin cancer (NMSC) are available. The market will be driven by the approval of these therapies because it will give patients new and varied treatment options
.Key Nonmelanoma Skin Cancer Companies: Genentech, Sanofi, Sirnaomics, AiViva BioPharma, Replimune, Ortho Dermatologics, Philogen S.p.A., AstraZeneca, Pfizer, and others
.Key Nonmelanoma Skin Cancer Therapies: VISMODEGIB (erivedge), LIBTAYO (cemiplimab-rwlc), STP705, AIV001, RP1, Tretinoin 0.1%, L19IL2 +L19TNF, Iressa, sirolimus, and others
.The Nonmelanoma Skin Cancer epidemiology based on gender analyzed that Men are two times more likely than women to develop basal cell carcinoma and three times more likely to develop squamous cell carcinoma than Women
.The Nonmelanoma Skin Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Nonmelanoma Skin Cancer pipeline products will significantly revolutionize the Nonmelanoma Skin Cancer market dynamics.
Nonmelanoma Skin Cancer Overview
Skin tumours that don't start out as melanoma are referred to as non-melanoma skin cancer. These more typical types of skin cancer are distinguished from the less frequent melanoma, which spreads more quickly in the body, by the name "non-melanoma."
Get a Free sample for the Nonmelanoma Skin Cancer Market Report
Nonmelanoma Skin Cancer Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Nonmelanoma Skin Cancer Epidemiology Segmentation:
The Nonmelanoma Skin Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
.Total prevalent cases of NMSC in the 7MM (Basal cell carcinoma, Squamous cell carcinoma
.Total diagnosed prevalent cases of NMSC in the 7MM
.Treatable cases of NMSC in the 7MM
.Gender-specific diagnosed prevalent cases of NMSC in the 7MM
.Region-specific diagnosed prevalent cases of NMSC in the 7MM
.Age-specific diagnosed prevalent cases of NMSC in the 7MM
Download the report to understand which factors are driving Nonmelanoma Skin Cancer epidemiology trends @ Nonmelanoma Skin Cancer Epidemiology Forecast
Nonmelanoma Skin Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Nonmelanoma Skin Cancer market or expected to get launched during the study period. The analysis covers Nonmelanoma Skin Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Nonmelanoma Skin Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Nonmelanoma Skin Cancer Therapies and Key Companies
.VISMODEGIB (erivedge): Genentech
.LIBTAYO (cemiplimab-rwlc): Sanofi
.STP705: Sirnaomics
.AIV001: AiViva BioPharma
.RP1: Replimune
.Tretinoin 0.1%: Ortho Dermatologics
.L19IL2 +L19TNF: Philogen S.p.A.
.Iressa: AstraZeneca
.sirolimus: Pfizer
Scope of the Nonmelanoma Skin Cancer Market Report
.Study Period: 2020–2034
.Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
.Key Nonmelanoma Skin Cancer Companies: Genentech, Sanofi, Sirnaomics, AiViva BioPharma, Replimune, Ortho Dermatologics, Philogen S.p.A., AstraZeneca, Pfizer, and others
.Key Nonmelanoma Skin Cancer Therapies: VISMODEGIB (erivedge), LIBTAYO (cemiplimab-rwlc), STP705, AIV001, RP1, Tretinoin 0.1%, L19IL2 +L19TNF, Iressa, sirolimus, and others
.Nonmelanoma Skin Cancer Therapeutic Assessment: Nonmelanoma Skin Cancer current marketed and Nonmelanoma Skin Cancer emerging therapies
.Nonmelanoma Skin Cancer Market Dynamics: Nonmelanoma Skin Cancer market drivers and Nonmelanoma Skin Cancer market barriers
.Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
.Nonmelanoma Skin Cancer Unmet Needs, KOL's views, Analyst's views, Nonmelanoma Skin Cancer Market Access and Reimbursement
To know more about Nonmelanoma Skin Cancer companies working in the treatment market, visit @ Nonmelanoma Skin Cancer Clinical Trials and Therapeutic Assessment
Table of Contents
1. Nonmelanoma Skin Cancer Market Report Introduction
2. Executive Summary for Nonmelanoma Skin Cancer
3. SWOT analysis of Nonmelanoma Skin Cancer
4. Nonmelanoma Skin Cancer Patient Share (%) Overview at a Glance
5. Nonmelanoma Skin Cancer Market Overview at a Glance
6. Nonmelanoma Skin Cancer Disease Background and Overview
7. Nonmelanoma Skin Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of Nonmelanoma Skin Cancer
9. Nonmelanoma Skin Cancer Current Treatment and Medical Practices
10. Nonmelanoma Skin Cancer Unmet Needs
11. Nonmelanoma Skin Cancer Emerging Therapies
12. Nonmelanoma Skin Cancer Market Outlook
13. Country-Wise Nonmelanoma Skin Cancer Market Analysis (2020–2034)
14. Nonmelanoma Skin Cancer Market Access and Reimbursement of Therapies
15. Nonmelanoma Skin Cancer Market Drivers
16. Nonmelanoma Skin Cancer Market Barriers
17. Nonmelanoma Skin Cancer Appendix
18. Nonmelanoma Skin Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Dr. Vishal Agrawal
DelveInsight Business Research
+1 469-945-7679
email us here
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
MENAFN17122024003118003196ID1109002604
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.